Manish GOYANİ, Meghraj SURYAWANSHİ, Ridhdhesh JIVAWALA

LEVOTİROKSİN SODYUMUN KONTROLLÜ SALIMI İÇİN IN-SITU PARENTERAL BİYOBOZUNUR İMPLANT FORMÜLASYONU VE DEĞERLENDİRİLMESİ

Amaç: Mevcut araştırmanın amacı, kontrollü levotiroksin sodyum salımı için parenteral in-situ oluşan biyobozunur implantın formülasyonu ve değerlendirilmesidir.

Anahtar Kelimeler:

Biyobozunur polimerler, ISFI, ISM, in-situ implant, solvent değişim tekniği

FORMULATION AND EVALUATION OF PARENTERAL IN-SITU FORMING BIODEGRADABLE IMPLANT FOR CONTROLLED RELEASE OF LEVOTHYROXINE SODIUM

Objective: The objective of present research work is formulation and evaluation of parenteral in-situ forming biodegradable implant for controlled release of levothyroxine sodium.

Keywords:

Biodegradable polymers, ISFI, ISM, in-situ implant, solvent exchange technique,

PDF

___

1. Gaitonde, D.Y., Rowley, K.D., Sweeney, L.B. (2012). Hypothyroidism: an update. South African Family Practice, 54(5), 384-390. [CrossRef]
2. Colucci, P., Yue, C.S., Ducharme, M., Benvenga, S. (2013). A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. European Endocrinology, 9(1), 40-47. [CrossRef]
3. Hays, M.T. (2007). Parenteral thyroxine administration. Thyroid, 17(2), 127-129. [CrossRef]
4. Abdelghany, S., Tekko, I.A., Vora, L., Larrañeta, E., Permana, A.D., Donnelly, R.F. (2019). Nanosuspension-based dissolving microneedle arrays for intradermal delivery of curcumin. Pharmaceutics, 11(7), 308. [CrossRef]
5. Sudhakar, M., Kancharla, R., Rao, V.U. (2013). A review on sustained release injectable depot drug delivery systems. International Journal of Advanced Pharmaceutical Sciences, 4, 142-58.
6. Sheikh, A.A., Sheikh, S.R. (2016). Advanced injectable drug delivery system: A brief review. System, 9(1), 11.
7. Chaker L, Bianco A, Peeters R. (2017). Hypothyroidism. Lancet, 390(1), 1550-1562. [CrossRef]
8. Kamaly, N., Yameen, B., Wu, J., Farokhzad, O.C. (2016). Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release. Chemical Reviews, 116(4), 2602-2663. [CrossRef]
9. Liechty, W.B., Kryscio, D.R., Slaughter, B.V., Peppas, N.A. (2010). Polymers for drug delivery systems. Annual Review of Chemical and Biomolecular Engineering, 1(1), 149-173. [CrossRef]
10. Joshi, J.R., Patel, R.P. (2012). Role of Biodegradable Polymers in Drug Delivery. International Journal of Current Pharmaceutical Research, 4(2), 74-81.
11. Song, R., Murphy, M., Li, C., Ting, K., Soo, C., Zheng, Z. (2018). Current development of biodegradable polymeric materials for biomedical applications. Drug Design, Development and Therapy, 12(1), 3117-3145. [CrossRef]
12. Singh, G., Kaur, T., Kaur, R., Kaur, A. (2014). Recent biomedical applications and patents on biodegradable polymer-PLGA. International Journal of Pharmacology and Pharmaceutical Science, 1(2), 30-42.
13. Han, F.Y., Thurecht, K.J., Whittaker, A.K., Smith, M.T. (2016). Bioerodable PLGA-based microparticles for producing sustained-release drug formulations and strategies for improving drug loading. Frontiers in Pharmacology, 7(1), 185. [CrossRef]
14. Madan, M., Bajaj, A., Lewis, S., Udupa, N., Baig, J.A. (2009). In situ forming polymeric drug delivery systems. Indian Journal of Pharmaceutical Sciences, 71(3), 242-251. [CrossRef]
15. Patel, B., Chakraborty, S. (2016). Biodegradable polymers: emerging excipients for the pharmaceutical and medical device industries. Journal of Excipients and Food Chemicals, 4(4), 1010.
16. Kapoor, D.N., Bhatia, A., Kaur, R., Sharma, R., Kaur, G., Dhawan, S. (2015). PLGA: A unique polymer for drug delivery. Therapeutic Delivery, 6(1), 41-58. [CrossRef]
17. Makadia, H.K., Siegel, S.J. (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers, 3(3), 1377-1397. [CrossRef]
18. Avachat, A.M., Kapure, S.S. (2014). Asenapine maleate in situ forming biodegradable implant: An approach to enhance bioavailability. International Journal of Pharmaceutics, 477(1-2), 64-72. [CrossRef]
19. Ahmed, T.A., Ibrahim, H.M., Samy, A.M., Kaseem, A., Nutan, M.T., Hussain, M.D. (2014). Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: In vitro release, pharmacokinetics, and stability. AAPS PharmSciTech, 15(3), 772–780. [CrossRef]
20. Algin-Yapar, E., Ari, N., Baykara, T. (2014). Evaluation of in vitro and in vivo performance of granisetron in situ forming implants: effect of sterilization, storage condition and degradation. Tropical Journal of Pharmaceutical Research, 13(3), 319-325. [CrossRef]
21. Bindu, R., Srinivas, P., Ravindrababu, D. (2015). Formulation and characterization of parenteral in situ implants of tariquidar bimesylate. International Journal of Pharmaceutical Sciences and Research, 6(1), 2028-2034.
22. Patel, R.B., Carlson, A.N., Solorio, L., Exner, A.A. (2010). Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems. Journal of Biomedical Materials Research Part A, 94(2), 476-484. [CrossRef]
23. Yehia, S.A., Abdel-Halim, S.A., Aziz, M.Y. (2017). Formulation and evaluation of injectable in situ forming microparticles for sustained delivery of lornoxicam. Drug Development and Industrial Pharmacy, 43(2), 319-328. [CrossRef]
24. Costa, P., Lobo, J.M.S. (2001). Modeling and comparison of dissolution profiles. European Journal of Pharmaceutical Sciences, 13(2), 123-133. [CrossRef]
25. Shaikh, H., Kshirsagar, R. (2015). Mathematical models for drug release characterization: A review. World Journal of Pharmaceutical Research, 4(4), 324-338.
26. Shintani, S., Yamazaki, M., Nakamura, M., Nakayama, I. (1967). A new method to determine the irritation of drugs after intramuscular injection in rabbits. Toxicology and Applied Pharmacology, 11(2), 293-301. [CrossRef]
27. Bajaj, S., Singla, D., Sakhuja, N. (2012). Stability testing of pharmaceutical products. Journal of Applied Pharmaceutical Science, 2(3), 129-138. [CrossRef]